Susan Galbraith on AstraZeneca’s Grand Presence at ASH25
Susan Galbraith, Executive Vice President Oncology Haematology R&D at AstraZeneca, shared on LinkedIn:
”It’s been a great few days at ASH25, and I am very proud that AstraZeneca had its largest presence to date, reflecting our haematology research strategy in action.
We shared scientific updates on our T‑cell engager research targeting CD19 and on cell therapy approaches, including our investigational BCMAxCD19 CAR‑T programme.
These efforts are focused on better understanding immune‑based approaches in blood cancers and coming away from ASH I’m encouraged by the science and collaboration I saw in action as we work to advance the next wave of blood cancer care.
For a closer look at some of these scientific developments, Anas Younes the latest article provides more detail.”
All from ASH25 featured in Hemostasis Today.
-
Sep 11, 2026, 17:41Khaled Musallam: Earlier Recognition, Better Outcomes in NTDT
-
Sep 11, 2026, 17:29Reyhan Kose Cobanoglu: APS ACTION Registry Study Published in Lupus
-
Sep 11, 2026, 17:14Obi Light Ogbonnia: From Kenya to Global Sickle Cell Advocacy
-
Sep 11, 2026, 17:01EAHAD 2027 Marks 20 Years
-
Sep 11, 2026, 16:54Denise Braendgaard: Reimagining Health Systems Through Collective Action
-
Sep 11, 2026, 16:47Jehad Khamaysa: Budd-Chiari Syndrome as the Initial Presentation of Behçet’s Disease in a 16-Year-Old
-
Sep 11, 2026, 16:44Mostafa Faisal Mohammed Saleh: From HLA Biology to Curative Therapy
-
Sep 11, 2026, 16:38Jim Kaveney: Class I, Level A – Lifestyle is Now the Official Standard in AFib Care
-
Sep 11, 2026, 16:31George Touma: Do We Really Need to Implant Metal in Every High-Bleeding-Risk Patient?